BioPharmSignal logoBioPharmSignal

Biotech News

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

Oric Pharmaceuticals, Inc. (ORIC)Oric Pharmaceuticals, Inc.Earnings

Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data

Related news

ORICOric Pharmaceuticals, Inc.2026-08-03 20:05 EST

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

ORICOric Pharmaceuticals, Inc.2026-07-20 12:30 EST

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

View all latest news

Oric Pharmaceuticals, Inc.

Oncology Resistance Biology ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments. Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is...

Recent company news

ORICOric Pharmaceuticals, Inc.2026-08-07 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-08-03 20:05 EST

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

ORICOric Pharmaceuticals, Inc.2026-07-20 12:30 EST

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

ORICOric Pharmaceuticals, Inc.2026-07-14 20:05 EST

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORICOric Pharmaceuticals, Inc.2026-07-02 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
14.20 USD
Market cap
788.8M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States